Mounjaro 15 mg 1 pen
Eli Lilly
Eli Lilly
Composition
Tirzepatide 15 mg per dose.
Excipients: solution for injection.
Properties of the Product
Dual GIP and GLP-1 receptor agonist.
Improve glycemic control in adults with type 2 diabetes.
Supports weight reduction and metabolic health.
Indications for Use
Type 2 diabetes mellitus in adults, as monotherapy or in combination with other antihyperglycemic agents.
Investigated for obesity management.
Method of Administration and Dosage
Subcutaneous injection, once weekly.
Starting dose: 2.5 mg per week, with gradual escalation to 5-15 mg depending on tolerance and clinical response.
Injection sites: abdomen, thigh, or upper arm.
Contraindications
Hypersensitivity to tirzepatide or excipients.
Personal/family history of medullary thyroid carcinoma.
Patients with multiple endocrine neoplasia syndrome type 2.
Precautions
Risk of thyroid tumors.
Monitor for pancreatitis symptoms.
Not recommended in type 1 diabetes or diabetic ketoacidosis.
May delay absorption of oral medications.
Adverse Reactions / Side Effects
Common: nausea, vomiting, diarrhea, decreased appetite, constipation.
Serious: pancreatitis, hypoglycemia (with insulin/sulfonylureas), hypersensitivity reactions, thyroid tumors (rare).
Pregnancy and Lactation
Not recommended during pregnancy or breastfeeding due to limited data.
Should only be used under medical supervision if benefits outweigh risks.
Storage Conditions
Store refrigerated at 2-8°C.
May be kept at room temperature (≤30°C) for up to 21 days.
Packaging
Carton with 1 pre-filled pen containing 4 doses.